Dependence on Specific Sales Partners
First written in FY2016. 4 of 8 entries say "Materialised", first in FY2018-Q1. Latest entry: FY2024-Q3.
Seikagaku moved to the "Worse" side of this theme in 2017, 6 years before the typical company in this theme (2023).
The whole theme swung hardest in 2017: 4 of 15 companies on the "Worse" side.
11 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「The company's sales of MucoUp, an endoscopic submucosal injection material, increased because of inventory adjustments by the sales partner.」
Dependence on sales partners' shipment and inventory management continued, as inventory adjustments by a sales partner increased the company's sales of MucoUp. - FY2023-Q2MitigatedAnnual report
「Lockdowns in major cities continued following the resurgence of COVID-19, and local sales of Alts in China declined substantially. The company's sales also declined substantially because there were no first-quarter shipments in connection with changes to packaging materials. Shipments resumed in August 2022 under the annual shipment plan.」
There were no first-quarter shipments under the sales partner's annual shipment plan, but shipments resumed in August 2022. Meanwhile, the company's sales declined substantially on a first-half cumulative basis. - FY2023-Q1MaterialisedAnnual report
「Local sales of Alts in China declined substantially because the rate of medical consultations fell as a result of renewed lockdowns in major cities following the resurgence of COVID-19. The company made no shipments in the first quarter under its annual shipment plan because the sales partner had built up inventory in the previous fiscal year in connection with changes to packaging materials. Shipments are scheduled to resume in August 2022.」
Because the sales partner had built up inventory and under the annual shipment plan, there were no first-quarter shipments of Alts for China, and dependence on the timing of shipments to sales partners was reflected in the results. - FY2022-Q2MaterialisedAnnual report
「The company's sales of MucoUp, an endoscopic submucosal injection material, increased because shipments to sales partners were brought forward.」
The impact of shipment timing to sales partners was reflected in the results as an increase in the company's sales of MucoUp. - FY2020-Q1MaterialisedAnnual report
「In addition, there were no sales in the first quarter because of the annual shipment plan for sales partners.」
Because of the annual shipment plan for sales partners, the company recorded no sales of Hernicore in the quarter. Dependence on the timing of shipments to sales partners was reflected in quarterly results. - FY2018-Q1MaterialisedAnnual report
「Consolidated net sales for the first quarter cumulative period (1 April 2017 to 30 June 2017) were ¥7,508 million, down 9.3% from the same period of the previous year. Sales were affected by the reaction to concentrated shipments of domestic Alts in the same period of the previous year and inventory adjustments at some overseas sales partners.」
Inventory adjustments at some overseas sales partners actually emerged as a factor behind the 9.3% year-on-year decline in consolidated sales. - FY2017RestatedAnnual report
「The company's main products, prescription pharmaceuticals and medical devices, are covered by exclusive sales agreements with sales partners, limiting the number of customers to which they are sold.」
The disclosure reiterates the structure in which sales of the company's main products depend on exclusive sales partners. - FY2016First statedAnnual report
「The company's main products, prescription pharmaceuticals and medical devices, are covered by exclusive sales agreements with sales partners, limiting the number of customers to which they are sold.」
The company has exclusive sales agreements for its major products in Japan and overseas, indicating that changes in the terms of transactions with sales partners may affect its performance.